Instead, other pulmonary and hepatic metastatic sites still maintaining the EGFR/FGFR3 co-mutations showed progression 6 months later associated with the appearance of the erlotinib-resistant T790M EGFR-mutation at very low AF. The gene discussed is EGFR; the disease is atrial fibrillation.